

WKN: 941135 / ISIN: LU0119891520

MEDICAL BioHEALTH

THE BIOTECH FUND MANAGED BY SCIENTISTS
SMALL COMPANIES FIGHTING BIG DISEASES

FUNDS MANAGER

Mario Linimeier



Managing Partner Mario Linimeier, a molecular biologist and economist, has managed MEDICAL BioHealth since 2017. He studied at the University of Vienna, Kepler University Linz, and Seoul National University.

Kristoffer Karl Unterbruner



Kristoffer Karl Unterbruner has been managing MEDICAL BioHealth as co-fund manager since 2022. He is a trained biotechnologist with specializations in immunology and gene therapy.



Investing in a healthy future:

Each selected company has the potential to significantly **improve existing therapies or make previously untreatable diseases manageable.**


INVESTMENT STRATEGY

- **Pioneering advances:** Numerous therapeutic areas are experiencing significant breakthroughs due to technological progress
- **Promising biotech companies:** Focus on developing novel and modern active substances to combat various diseases
- **Focus on small and medium-sized companies:** These companies show above-average innovation and high value-creation dynamics

PROFILE HIGHLIGHTS

- **Scientists as portfolio managers:** This expertise allows for a deep understanding of complex interrelationships and early identification of medical breakthroughs
- **Proven Investment Success:** Over 20 years of consistent outperformance compared to healthcare indices by investing in a diverse portfolio (70-100 individual stocks)
- **Future Potential:** Combining biotech with technological developments like AI and digitalization opens new, unprecedented opportunities for medical advancements.

PERFORMANCE SINCE INCEPTION 30 OCTOBER 2000 (AS AT: 1HY/2024)



As at: 28 June 2024; Source: vwd; Price indices in EUR; The previous day's closing prices were used to calculate the index performance and the exchange rate conversion. As the fund is mainly invested in North America, the time difference was taken into account. Fund: Performance calculation based on gross performance (BVI method). The front-end load (for investment and reinvestment) was not taken into account, nor were individual costs such as custody fees included. If the front-end load and custody fees were included, the performance would be lower. Past performance is not an indicator of future performance and is no guarantee of future success.

Performance 5 years (in %; as at 1HY/2024)

	Jan	Feb	March	April	May	June	July	Aug	Sep	Oct	Nov	Dec	Year
2019	11.9	8.7	2.5	0.2	-2.5	2.7	3.0	-3.9	-3.1	2.6	11.9	4.8	44.1
2020	-2.4	-3.0	-12.1	24.2	5.6	1.0	-5.1	-2.5	3.3	2.3	7.7	1.4	17.5
2021	5.6	-2.3	-2.4	-0.3	-4.2	4.9	-5.4	4.3	-1.4	0.9	-7.4	0.1	-8.3
2022	-12.4	2.3	3.6	-5.7	-8.3	9.3	8.6	6.9	-2.7	1.7	-6.9	-1.0	-7.2
2023	4.6	-0.3	-7.7	2.3	7.2	2.8	5.3	-3.5	-3.1	-9.7	2.2	20.9	19.3
2024	2.7	11.2	-3.3	-5.4	-0.2	3.7							8.1

As at 28/06/2024; source: Anevis GmbH; Calculation based on gross performance (BVI method), i.e. without taking the front-end load into account. Past performance is not a reliable indicator of future performance. The gross performance (BVI method) takes into account all costs incurred at fund level (e.g. the management fee), excluding the front-end load. Further costs may be incurred individually at client level (e.g. custody account fees, commissions and other charges). Model calculation (net): An investor wishes to purchase units for EUR 1000. With a maximum front-end load of 5%, he must pay a one-off fee of EUR 50 at the time of purchase. In addition, custody account costs may be incurred which reduce the performance. The custody account costs can be found in your bank's list of prices and services.

TODAY, NEW INNOVATIVE THERAPIES ARE MAINLY DEVELOPED BY BIOTECH COMPANIES

The future of biotechnology - quantum leaps in medicine

Breakthrough advances expected in many therapeutic areas

The **billion-dollar assault** on cancer

More than **30 million people** with rare diseases



Autoimmune diseases:
High demand for new therapies

Diseases of the central nervous system:
New approaches against Alzheimer's & Co.

Cardiometabolic diseases:
Cardiovascular and metabolic diseases as **#1 cause of death**



"We continuously analyze and evaluate approximately 900 small and mid-cap companies that are not on the radar of many investors. Above-average growth is generated primarily by these small, research-oriented companies."

Mario Linimeier, Managing Partner at Medical Strategy GmbH



www.medicalstrategy.de



Opportunities

- participation in the global growth of the healthcare market
- portfolio of carefully selected companies
- focussing on developers of innovative therapies
- expertise of an interdisciplinary team of experts with a scientific background

Risiks

- price risk
- misjudgement of the investment selection is possible
- specific risks of drug development
- market risk
- liquidity risks
- currency risks

Disclaimer: This document is a marketing communication. It cannot replace an individual consultation, does not constitute investment advice or a solicitation to buy or sell shares and serves solely to describe the product. It is not a financial analysis and therefore does not have to meet all legal requirements regarding the impartiality of financial analyses. It is therefore not subject to a ban on trading prior to the publication of financial analyses. Further detailed information on the opportunities and risks can be found in the sales prospectus and the key information document. The sales prospectus, the key information document and the associated semi-annual and annual reports are the sole binding basis for the purchase of fund units. They are available from the management company Hauck & Aufhäuser Fund Services S.A., 1c, rue Gabriel Lippmann 5365 Munsbach, Luxembourg and at <https://medicalstrategy.de/fonds/medical-bio-health>. The statements of opinion contained in this product information reflect the current, carefully prepared assessment of Medical Strategy GmbH; these may change at any time without prior notice.

Past performance is not a reliable indicator of current and future performance and losses are possible. Investment funds are subject to market-related price fluctuations, which can lead to losses of the capital invested.